3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
capmatinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled